Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | EP300 | Q09472 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19736987 | 0.81 | KDM4C (0.35) | KDM4CL3MBTL1NPC1RAB9AEP300 | |
| SCHEMBL17658749 | 0.77 | KDM4C (0.35) | KDM4CL3MBTL1NPC1RAB9AEP300 | |
| SCHEMBL17649327 | 0.72 | L3MBTL1 (0.43) | KDM4CL3MBTL1NPC1RAB9ACREBBP | |
| SCHEMBL15280629 | 0.72 | KDM4C (0.43) | KDM4CL3MBTL1NPC1RAB9ACREBBP | |
| SCHEMBL15633486 | 0.69 | MAPK1 (0.44) | KDM4CL3MBTL1NPC1RAB9AEP300 | |
| SCHEMBL15639233 | 0.69 | MAPK1 (0.44) | KDM4CL3MBTL1NPC1RAB9AEP300 | |
| SCHEMBL15280618 | 0.68 | KDM4C (0.39) | KDM4CL3MBTL1NPC1RAB9ACREBBP | |
| SCHEMBL17649727 | 0.68 | KDM4C (0.39) | KDM4CL3MBTL1NPC1RAB9ACREBBP | |
| SCHEMBL24252783 | 0.67 | KDM4C (0.38) | KDM4CL3MBTL1NPC1RAB9ACREBBP | |
| SCHEMBL507078 | 0.67 | NAAA (0.46) | KDM4CL3MBTL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550778-B2 | Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5 | VANDERBILT UNIVERSITY (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550778-B2 | Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5 | VANDERBILT UNIVERSITY (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550778-B2 | Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5 | VANDERBILT UNIVERSITY (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160096833-A1 | SUBSTITUTED 6-ARYL-IMIDAZOPYRIDINE AND 6-ARYL-TRIAZOLOPYRIDINE CARBOXAMIDE ANALOGS AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR5 | VANDERBILT UNIVERSITY | 2016-04-07 | — | — | US | disclosed |
| US-20160096833-A1 | SUBSTITUTED 6-ARYL-IMIDAZOPYRIDINE AND 6-ARYL-TRIAZOLOPYRIDINE CARBOXAMIDE ANALOGS AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR5 | VANDERBILT UNIVERSITY | 2016-04-07 | — | — | US | disclosed |
| US-20160096833-A1 | SUBSTITUTED 6-ARYL-IMIDAZOPYRIDINE AND 6-ARYL-TRIAZOLOPYRIDINE CARBOXAMIDE ANALOGS AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR5 | VANDERBILT UNIVERSITY | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096833-A1 | SUBSTITUTED 6-ARYL-IMIDAZOPYRIDINE AND 6-ARYL-TRIAZOLOPYRIDINE CARBOXAMIDE ANALOGS AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR5 | GRM5, GRIK5, GRM2 | KDM4C 2085/4885L3MBTL1 3170/4885NPC1 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.